<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSCs</z:chebi>) are notorious for their capacity of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e>, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> or resistance to chemo-radiotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>However, the undisputed role of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem marker, CD133, in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) is not clear yet </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We assessed 271 surgically-resected stage II and III primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> with (171) and without (100) adjuvant therapy after surgery </plain></SENT>
<SENT sid="3" pm="."><plain>CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR </plain></SENT>
<SENT sid="4" pm="."><plain>CD133 promoter methylation was quantified by pyrosequencing </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The CD133 IHC expression was significantly correlated with <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression (p=0.0257) and inversely correlated with the promoter methylation (p=0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>CD133 was expressed more frequently in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> (p=0.0035), and in moderately differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (p=0.0378) </plain></SENT>
<SENT sid="7" pm="."><plain>In survival analysis, CD133 expression was not significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103) </plain></SENT>
<SENT sid="8" pm="."><plain>However, CD133+ <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were significantly associated with better OS in patients with adjuvant therapy compared to those without adjuvant therapy (p&lt;0.0001, HR 0.125, 95% CI 0.052-0.299) </plain></SENT>
<SENT sid="9" pm="."><plain>But the patients with CD133- <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR 0.500, 95% CI 0.247-1.015) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In stage II and III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>, CD133 IHC expression may signify the benefit for adjuvant therapy although it is not an independent prognostic factor </plain></SENT>
</text></document>